D(
Daniel (Dan) Skovronsky, M.D., Ph.D.
EVP, Chief Scientific and Medical Officer, President of Lilly Research Laboratories
Eli LillyTherapeutic Areas
Eli Lilly Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tirzepatide (Mounjaro/Zepbound) | Type 2 Diabetes | Launched |
| Tirzepatide | Obstructive Sleep Apnea | Phase 3 |
| Donanemab | Early Symptomatic Alzheimer's Disease | Regulatory Review |
| Lebrikizumab | Moderate-to-Severe Atopic Dermatitis | Regulatory Review |
| Retatrutide | Obesity | Phase 3 |
| Orforglipron | Type 2 Diabetes & Obesity | Phase 3 |
| Mirikizumab | Ulcerative Colitis | Regulatory Review |
| Pirtobrutinib (Jaypirca) | Mantle Cell Lymphoma & CLL/SLL | Launched/Phase 3 |
Leadership Team at Eli Lilly
DA
David A. Ricks
Chairman and Chief Executive Officer
AA
Anat Ashkenazi
EVP and Chief Financial Officer
PJ
Patrik Jonsson
EVP, President of Lilly Immunology and Lilly USA, Chief Customer Officer
IY
Ilya Yuffa
EVP and President of Lilly International
FC
Frank Cunningham
EVP, Global Manufacturing and Quality